Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (151-160 of 791) with videos related to

Pageof 80
Sort By:
Cancer|November 25, 2003
Imatinib mesylate causes hypopigmentation in the skinAnne S Tsao, Hagop Kantarjian, Jorge Cortes, et al.
Leukemia & Lymphoma|January 3, 2013
Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosisAlfonso Quintás-Cardama, Matjaz Sever, Jorge Cortes, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 9, 2013
Prognostic model to identify patients with myelofibrosis at the highest risk of transformation to acute myeloid leukemiaAlfonso Quintás-Cardama, Hagop Kantarjian, Sherry Pierce, et al.
Blood|May 31, 2007
Farnesyl transferase inhibitor resistance probed by target mutagenesisTal Raz, Valentina Nardi, Mohammad Azam, et al.
Blood|December 4, 2010
Competing cell clones in myeloproliferative neoplasmAref Al-Kali, Srdan Verstovsek, Hagop Kantarjian, et al.
Haematologica|May 2, 2009
Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trialsRichard T Silver, Jorge Cortes, Roger Waltzman, et al.
Leukemia Research|July 20, 2002
Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylatePatricia Ault, Jorge Cortes, Charles Koller, et al.
JAMA Network Open|March 16, 2026
Geographic, Racial, and Sex Disparities in Time to Treatment for Early-Onset Colorectal CancerMeng-Han Tsai, Steven S Coughlin, Jorge Cortes, et al.
Cancer|March 9, 2010
Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapiesElias Jabbour, Deborah Thomas, Jorge Cortes, et al.
Cancer Journal (Sudbury, Mass.)|December 14, 2011
Evolution of therapies for chronic myelogenous leukemiaFabio P S Santos, Hagop Kantarjian, Alfonso Quintás-Cardama, et al.
Pageof 80

Showing results (151-160 of 791) with videos related to

Sort By:
Pageof 80
Cancer|November 25, 2003
Imatinib mesylate causes hypopigmentation in the skinAnne S Tsao, Hagop Kantarjian, Jorge Cortes, et al.
Leukemia & Lymphoma|January 3, 2013
Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosisAlfonso Quintás-Cardama, Matjaz Sever, Jorge Cortes, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 9, 2013
Prognostic model to identify patients with myelofibrosis at the highest risk of transformation to acute myeloid leukemiaAlfonso Quintás-Cardama, Hagop Kantarjian, Sherry Pierce, et al.
Blood|May 31, 2007
Farnesyl transferase inhibitor resistance probed by target mutagenesisTal Raz, Valentina Nardi, Mohammad Azam, et al.
Blood|December 4, 2010
Competing cell clones in myeloproliferative neoplasmAref Al-Kali, Srdan Verstovsek, Hagop Kantarjian, et al.
Haematologica|May 2, 2009
Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trialsRichard T Silver, Jorge Cortes, Roger Waltzman, et al.
Leukemia Research|July 20, 2002
Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylatePatricia Ault, Jorge Cortes, Charles Koller, et al.
JAMA Network Open|March 16, 2026
Geographic, Racial, and Sex Disparities in Time to Treatment for Early-Onset Colorectal CancerMeng-Han Tsai, Steven S Coughlin, Jorge Cortes, et al.
Cancer|March 9, 2010
Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapiesElias Jabbour, Deborah Thomas, Jorge Cortes, et al.
Cancer Journal (Sudbury, Mass.)|December 14, 2011
Evolution of therapies for chronic myelogenous leukemiaFabio P S Santos, Hagop Kantarjian, Alfonso Quintás-Cardama, et al.
Pageof 80